Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland

por Çakar, Esra, Oniangue-Ndza, César, Schneider, Ralph P., Klijn, Sven L., Vogl, Ursula M., Rothermundt, Christian, May, Jessica R.
Publicado 2023

HIV-1 adaptation to NK cell mediated immune pressure

por Alter, Galit, Heckerman, David, Schneidewind, Arne, Fadda, Lena, Kadie, Carl M., Carlson, Jonathan M., Oniangue-Ndza, Cesar, Martin, Maureen, Li, Bin, Khakoo, Salim I., Carrington, Mary, Allen, Todd M., Altfeld, Marcus
Publicado 2011